SMILES: CS(=O)(=O)C1=C2[C@H](O)C(F)(F)CC2=C(OC2=CC(=CC(F)=C2)C#N)C=C1
Response: The PK properties of the drug with SMILES CS(=O)(=O)C1=C2[C@H](O)C(F)(F)CC2=C(OC2=CC(=CC(F)=C2)C#N)C=C1 are predicted as follows:

*   **Absorption:** Oral bioavailability is predicted to be **< 20%**, suggesting poor absorption via the oral route.
*   **Distribution:** It is predicted to have a **moderate volume of distribution (Vd approx. 0.5-1.5 L/kg)**, indicating it distributes reasonably well into tissues.
*   **Metabolism:** The drug is predicted to be a **substrate for CYP3A4**, suggesting it will be metabolized by this major cytochrome P450 enzyme. It also shows **potential inhibition of CYP2D6**, which could lead to drug-drug interactions if co-administered with CYP2D6 substrates.
*   **Excretion:** The drug is predicted to have a **moderate half-life (t1/2 approx. 6-12 hours)**, implying it would require dosing once or twice daily to maintain steady-state concentrations. Specific clearance pathways (e.g., renal vs. hepatic) are not definitively predicted, but metabolism by CYP3A4 suggests a hepatic component.
============================================================
SMILES: C1C2=C(C=CC(=C2[C@@H](C1(F)F)O)S(=O)(=O)C(F)F)OC3=CC(=CC(=C3)C#N)F
Response: The pharmacokinetic (PK) properties for the drug with SMILES C1C2=C(C=CC(=C2[C@@H](C1(F)F)O)S(=O)(=O)C(F)F)OC3=CC(=CC(=C3)C#N)F are predicted as follows:

*   **Oral Bioavailability:** < 20%
*   **Half-Life:** 10.00 hours
*   **Volume of Distribution (VDss):** 13.00 L/kg
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F
Error: 400 An internal error has occurred. Please retry or report in https://developers.generativeai.google/guide/troubleshooting
============================================================
SMILES: O=[N+]([O-])c1c(NCc2ccc(F)cc2Cl)ccc2nonc12
Response: Based on the predictions, the pharmacokinetic properties of the drug O=[N+]([O-])c1c(NCc2ccc(F)cc2Cl)ccc2nonc12 are:

*   **Oral Bioavailability:** Predicted to be less than 20%. This suggests poor absorption following oral administration, which could necessitate alternative routes of administration or formulation strategies to improve systemic exposure.
*   **Half-life:** Predicted to be 309.00 hours. This is a very long half-life, implying that the drug would remain in the body for an extended period. Such a long half-life could support less frequent dosing, but also means that steady-state levels would take a long time to achieve, and drug washout would be very slow if adverse effects occur.
*   **Volume of Distribution at Steady State (VDss):** Predicted to be 1.00 L/kg. This value suggests moderate distribution of the drug into tissues. A VDss around 1 L/kg indicates that the drug distributes beyond the plasma compartment into the total body water, but not extensively into peripheral tissues.
============================================================
SMILES: O=[N+]([O-])c1c(NCc2ccc(F)cc2C(F)(F)F)ccc2nonc12
Response: The predicted pharmacokinetic (PK) properties of the drug O=[N+]([O-])c1c(NCc2ccc(F)cc2C(F)(F)F)ccc2nonc12 are as follows:

*   **Oral Bioavailability:** Predicted to be < 20%.
*   **Half-Life:** Predicted to be 3.00 hours.
*   **Volume of Distribution (VDss):** Predicted to be 3.00 L/kg.
============================================================
